Q32 Bio
QTTB
106 hedge funds and large institutions have $89.7M invested in Q32 Bio in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 38 reducing their positions, and 25 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.43% less ownership
Funds ownership: 3.29% → 2.85% (-0.43%)
12% less funds holding
Funds holding: 120 → 106 (-14)
27% less capital invested
Capital invested by funds: $123M → $89.7M (-$33.4M)
29% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 38
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
97% less call options, than puts
Call options by funds: $102K | Put options by funds: $3.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$974K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$782K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$742K |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$690K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$516K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.71M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.52M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.21M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.37M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.23M |
QTTB Hedge Fund Activity: Q1 2022 in Review
106 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2022, worth a combined $89.7M — down 27% from $123M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of QTTB and 11 opened new positions — a net loss of 14 holders — while 38 trimmed existing stakes and 27 added.
The largest buyer was BlackRock, adding an estimated $974K. The largest seller was T. Rowe Price Associates, cutting an estimated $7.71M.
- 106 institutional investors held Q32 Bio (QTTB) as of Q1 2022, down from 120 in Q4 2021.
- Funds reported $89.7M of Q32 Bio stock for Q1 2022, down 27% quarter-over-quarter.
- 11 funds opened new Q32 Bio positions in Q1 2022 and 25 closed out, a net change of -14 holders.
- The largest Q32 Bio buyer in Q1 2022 was BlackRock, an estimated $974K added.
- The largest Q32 Bio seller in Q1 2022 was T. Rowe Price Associates, an estimated $7.71M sold.
Based on aggregated 13F filings for Q1 2022.